RxDoctor Payments Data

Vivianna Sanchez Arriela, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1679737456

Payments from drug & device makers

$1,985in general payments, 2019–2025

Across 77 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$593
  • AstraZeneca$534
  • Abbott$371
  • Novo Nordisk$140
  • Merck$93
  • Medtronic$58
  • plus $197 from 7 others

What the payments were for

  • Speaking & faculty fees$30015%
  • Food & beverage$1,67985%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC9$593
AstraZeneca27$534
Abbott19$371
Novo Nordisk7$140
Merck5$93
Medtronic1$58
PBG Puerto Rico LLC2$57
Boehringer Ingelheim2$48
Bayer Puerto Rico Inc.1$25
Bayer1$20
Dexcom, Inc.1$20
Johnson & Johnson1$14
Eli Lilly Export S.A. Puerto Rico Branch1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,985 in reported general payments places this provider in the 25th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,446
Medicare patients
39
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xigduo XrDapaglifloz Propaned/Metformin305$198,626
OzempicSemaglutide162$162,526
JardianceEmpagliflozin163$115,489
Synjardy XrEmpagliflozin/Metformin Hcl141$106,469
TrulicityDulaglutide100$102,833
FarxigaDapagliflozin Propanediol118$76,759
SynthroidLevothyroxine Sodium948$53,414
Janumet XrSitagliptin Phos/Metformin Hcl64$46,567
JanuviaSitagliptin Phosphate71$45,302
Soliqua 100-33Insulin Glargine/Lixisenatide35$39,028
SynjardyEmpagliflozin/Metformin Hcl50$32,320
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$25,866
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog45$23,121
GlyxambiEmpagliflozin/Linagliptin29$22,798
JanumetSitagliptin Phos/Metformin Hcl21$18,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi, Tradjenta$48$304,601421 claims
Novo NordiskOzempic$140$162,526162 claims
MerckJanumet Xr, Januvia, Janumet$93$110,016156 claims
AstraZenecaFarxiga$534$76,759118 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$593$47,129139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →